The Yangzi River is hanging! 4 varieties approved in that 25 over-rated varieties bar on the screen

Pharmaceutical Network July 9th, Yangzijiang to copy 4 types of generic drugs at the same time into the administrative approval stage, is expected to be approved for production in the near future and as equal to the evaluationMinnet data show that at present, Yangzijiang has 25 varieties (13 for the first), 21 were included in the national harvest; Leading the way, 74 varieties to the new classification of production (5 have been approved), 69 varieties in review have 22 annual sales of more than 1 billion, 21 varieties have not yet been approved for generic drugs, Yangzijiang and Zhengda Tianqing, Qilu, Koren and other enterprises to compete for the first4
generic drugs approved in that, 25
over-rated varieties bar-screentable 1: Yangzijiang Pharmaceutical srecently entered the administrative approval of products
July 1, Yangzijiang Pharmaceutical s4 generic drug listing applications at the same time into the administrative approval stage, is expected to be approved in the near future productionAll four varieties are reported in newly registered classifications and will be treated as consistent lying after being approved for productionDoso-sothelin is a derivative of methyl jaundice, which can be directly acting on the bronchial tube, relaxing the bronchial smooth muscle, and achieving the effect of suppressing asthmaAccording to Minet.com, sales of multi-so-base soda in 2019 in China's urban publichospitals
, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) exceeded 3 billion yuan, accounting for nearly 97% of injectionsDomestic 14 generic drug enterprises have a doso-alkali injection production approval, stone four drugs products the first reviewTofatibwas is the world's first small molecule-targeted JAK kinase inhibitor developed by Pfizer to treat rheumatoid arthritis, with global sales of $2.242 billion in 2019, up 26% year-on-yearDomestic has 3 generic drug enterprises product evaluation, Zhengda Qing took the first imitation and the first reviewDevandaban is the world's first oral Xa factor inhibitor developed jointly by Bayer and Johnson and Johnson forthrombosis-relateddiseases, with global sales of nearly $7 billion in 2019The product was approved to enter the domestic market in April 2009, and sales at the terminal of public medical institutions in China in 2019 amounted to 2.506 billion yuanThe newly developed immunomodulator anti-
tumordrug, with global sales of $10.823 billion in 2019The product was approved to enter the domestic market in January 2013, in November 2017, the first generic drug to naduamine was approved for market, flower-sized shuangyu pharmaceutical industry;Table 2: Yangzijiang has been evaluated varietiesNote: belt , included in the 4 plus 7 collection, s included in the second batch of collection, s to be included in the third batch of collectioncurrently Yangzijiang Pharmaceutical industry a total of 25 varieties through or as if passed by consistency evaluation 13 varieties for the first review, including cephalosporine acrylic tablets, Ipastama tablets, hydrochloric acid right metamine injection, hydrochloric acid trazere capsules, tabutafen tablets 5 varieties for exclusive reviewTwenty-one of the 25 evaluated varieties were included/proposed for national collectionGifitini, right Metomidin, Montitstone, Inapri, Erbesatan, ammonia chloration, chloratan for 4 plus 7 sets of varieties, the first collection and expansion of the collection, Yangzijiang has 2 varieties of winning bid, respectively, Inapri, right Metomidine; azithromycin, tradine, cephalosporine, cephalosporine, fluoro, cyclomelo, Conxaine for the second batch of varieties, Yangzijiang has 4 varieties of winning bid, respectively, fluorocon (3 winning bid), Meloda (2 winning bid), Traaquin (2 winning bid), Gremeya (5 winning bids);30 consistency evaluation varieties in the review, 23 over 1 billion injections to be released
Table 3: Yangzijiang in review of the consistency evaluation supplementary application varieties
currently Yangzijiang has 51 generic drug consistency evaluation supplementary applications received by CDE, of which 21 Has been successfully evaluated, in the review of 24 of the 30 varieties in China's public medical institutions in 2019 the annual sales of more than 1 billion yuan, injection with permeitus diazepam, injection of cephalosporine, injection of sodium radon more than 5 billion yuan 　　Of the 30 varieties under review, 26 were injectables, and 14 injectables increased in 2019 compared to 2018, with the injection of parisibas sodium, the hydroxixsasar sodium chloride injection, the injection of esiomeramazole, milin injections, the injection of pyrethic acid, the injection of permeycenic sodium, and the amount of iodine coctol 　　In addition to the injection of parisibb sodium, simvastatin tablets, hydrochloric acid moxixin sodium chloride injection, pyrethroid acid injection, injection with permeitus dsodium, iodine sea alcohol injection, dositase injection, hydrochloric acid sitrigrice tablets 8 varieties, the remaining 22 varieties have not yet been evaluated by enterprises 　　Injection with more cifiave, oxaxazole capsule, sequoia alcohol injection, fluconazole sodium chloride injection, hydrochloric acid left oxyfluorateinjection injection, injection with cephalosporine sodium, methylcobalamin injection 7 varieties by the first declaration of consistency evaluation by Yangzijiang, including oxazine capsule, hydrochloric acid ooxysacline injection, methyl cobalamin injection for exclusive declaration 　　Generic drug declaration leader, with Zhengda Qing, Qilu .. Grab the first imitation table 4: Yangzijiang with a new classification of generic drugs in the review
currently Yangzijiang has 74 varieties reported to the new registered classification, of which 5 have been approved for production and regarded as through the consistency evaluation, 22 of the 69 varieties under review are in In 2019, China's public medical institutions terminal sales of more than 1 billion yuan, including hydrochloric acid Palonosqiong injection, Doxithasai injection two super 1 billion varieties of "two-way power", both submitted a consistency evaluation supplementary application, but also to the new registration classification submitted to the listing application Table 5: No generics approved Yangzijiang in the review of 65 varieties of 21 in the domestic market has not yet been approved for generic drugs on the market The highest global sales varieties are the new base of Pomadoamine capsules, the product in 2019 global sales reached 2.525 billion U.S dollars, the original research has not been approved for import, Zhengda Tianqing, Yangzijiang, Qilu 3 enterprises to report to the new classification; Mercadong's Shumore sodium sodium 2019 global sales reached 1.131 billion U.S dollars, the original research has been approved for import, Koren, Yangzijiang, Zhengda Sunny, Dongsun medicine, Qilu and other 8 enterprises to seize the first imitation 　　From the variety competition situation, Fumaacid propofol noofovir tablets, hydrochloric acid Moxisa star eye drops, left oxyfluoratin sodium chloride injection, Su-more glucose sodium injection 4 varieties of competition is more intense, with the new classification of the number of enterprises up to 10 and above, of which Fumatophenol-noofovir tablets up to 14, the product in 2019 global sales of nearly 500 million U.S dollars, the domestic domestic sales of only domestic products 　　From the enterprise competition situation, 21 varieties, Zhengda Qing, Qilu, Koren, Hengrui, Dongsunshine medicine, Chengdu Bete, Yuandong Biology and other enterprises are layout 2 and above varieties, of which Zhengda Qing, Qilu, Kolun 3 enterprises layout 5 varieties, with Yangzijiang together to seize the first 　　Hydrobromic acid voltsulpystin tablets, hydrochloric acid right metomitins chloride sodium chloride injection, Ntikave oral solution 3 varieties were first reported by Yangzijiang with a new classification; The seven varieties of lupathaata-based oral solution, fentanyl hydrochloride cream, methicilladine tablets, compound electrolyte injection (III), and sodium acetate glycoglucose injection were reported exclusively by Yangzijiang with a new classification 　　Source: Minnet database
Note: statistics as of July 7, if there are omissions, welcome to point out!